Abstract | Our comprehensive analysis of alternative splicing across 32 The Cancer Genome Atlas cancer types from 8,705 patients detects alternative splicing events and tumor variants by reanalyzing RNA and whole-exome sequencing data. Tumors have up to 30% more alternative splicing events than normal samples. Association analysis of somatic variants with alternative splicing events confirmed known trans associations with variants in SF3B1 and U2AF1 and identified additional trans-acting variants (e.g., TADA1, PPP2R1A). Many tumors have thousands of alternative splicing events not detectable in normal samples; on average, we identified ≈930 exon-exon junctions (“neojunctions”) in tumors not typically found in GTEx normals. From Clinical Proteomic Tumor Analysis Consortium data available for breast and ovarian tumor samples, we confirmed ≈1.7 neojunction- and ≈0.6 single nucleotide variant-derived peptides per tumor sample that are also predicted major histocompatibility complex-I binders (“putative neoantigens”). A pan-cancer analysis by Kahles et al. shows increased alternative splicing events in tumors versus normal tissue and identifies trans-acting variants associated with alternative splicing events. Tumors contain neojunction-derived peptides absent in normal samples, including predicted MHC-I binders that are putative neoantigens. |
Recommended Citation GB/T 7714 |
Kahles A.,Lehmann K.-V.,Toussaint N.C.,et al. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients[J]. Cancer Cell, 2018, 34(2), 211-224.e6.
|
APA |
Kahles A.., Lehmann K.-V.., Toussaint N.C.., Huser M.., Stark S.G.., Sachsenberg T.., Stegle O.., Kohlbacher O.., Sander C.., Caesar-Johnson S.J.., Demchok J.A.., Felau I.., Kasapi M.., Ferguson M.L.., Hutter C.M.., Sofia H.J.., Tarnuzzer R.., Wang Z.., Yang L.., ...& Ratsch G. (2018). Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell, 34(2), 211-224.e6.
|
Edit Comment